Novacyt Share News (NCYT)
NCYT Share
NCYT Share
NCYT Share
NCYT Share
NCYT
NCYT Share
NCYT Level 2
NCYT Live
NCYT Broker
NCYT Directors
NCYT Financial
NCYT
NCYT Short
NCYT
Last checked at -
(Sharecast News) - Clinical diagnostics specialist Novacyt announced the planned launch of two 'PathFlow' Covid-19 antigen lateral flow tests on Tuesday, to strengthen its Covid-19 portfolio and to pursue significant new market opportunities, particularly in point-of-care settings.
Read more(Sharecast News) - Clinical diagnostics specialist Novacyt announced a more-than-twentyfold improvement in group consolidated revenue in its full-year results on Tuesday, to £277.2m, as its gross margin improved to 76.3% in 2020, from 64% in 2019.
Read more(Sharecast News) - Clinical diagnostics company Novacyt announced on Monday that its 'SNPsig' SARS-CoV-2 polymerase chain reaction (PCR) genotyping portfolio has been included in the NHS England framework for detecting Covid-19 'variants of concern'.
Read more(Sharecast News) - Clinical diagnostics specialist Novacyt updated the market on the progress of its near-term Covid-19 research and development programmes on Friday, addressing "rapidly-evolving" testing demands, particularly as SARS-CoV-2 continued to mutate globally.
Read more(Sharecast News) - Novacyt said on Friday that a dispute with the Department of Health and Social Care (DHSC) over a supply contract could have a "material" impact on fourth-quarter revenues and dent 2021 profit and revenue, sending its shares sharply lower.
Read more(Sharecast News) - Clinical diagnostics specialist Novacyt announced the launch of 'SNPsig VariPLEX' on Wednesday, as a CE-marked polymerase chain reaction (PCR) assay panel, able to detect the four currently-recognised Covid-19 variants of concern, and the two most biologically significant mutations, in a single kit.
Read more(Sharecast News) - Clinical diagnostics specialist Novacyt announced the expansion of its 'VersaLab' service on Wednesday, with the launch of mobile processing laboratories to provide rapid turnaround polymerase chain reaction (PCR) testing on-site.
Read more(Sharecast News) - Clinical diagnostics company Novacyt updated the market on the progress of its near-term research and development programmes on Wednesday, including the expansion of its product portfolio, clinical trial activity and the publication of independent validations of its Covid-19 tests.
Read more(Sharecast News) - Clinical diagnostics company Novacyt announced the launch of a new portfolio of assays under the brand name 'SNPsig' on Tuesday, to aid the diagnosis of the new variants of SARS-CoV-2, the virus which causes the Covid-19 disease.
Read more(Sharecast News) - Clinical diagnostics firm Novacyt said on Friday that full-year revenues had surged in 2020, driven by the continued successful global commercialisation of its Covid-19 product portfolio.
Read more(Sharecast News) - Clinical diagnostics company Novacyt announced on Tuesday that James McCarthy has been appointed as chief financial officer, while Anthony Dyer has taken on a new role as chief corporate development officer (CCDO).
Read more(Sharecast News) - Novacyt shares surged on Monday after the clinical diagnostics specialist said that its tests can detect the new strain of Covid-19 identified by the UK's Genomics consortium, known as VUI-202012/01.
Read more(Sharecast News) - Clinical diagnostics company Novacyt announced the launch of its research-use-only polymerase chain reaction test for a new strain of Covid-19 on Monday, as well as the development of two new research-use0only polymerase chain reaction tests for avian influenza, following recent outbreaks across Europe.
Read more(Sharecast News) - Covid-19 test maker Novacyt swung to a first-half profit driven by soaring sales during the current pandemic and said it expected core annual earnings to top €100m.
Read more(Sharecast News) - Clinical diagnostics company Novacyt announced on Friday that it has launched a CE-marked polymerase chain reaction (PCR) two-gene target test for Covid-19.
Read more
Last checked at